Exosomes are small vesicles (60±100 nm) secreted by various cell types upon the fusion of endosomal compartments with the plasma membrane. Exosomes from antigen-presenting cells (APC), such as B lymphocytes and dendritic cells (DC), bear MHC class II molecules. In addition, the injection of DC-derived exosomes was reported to elicit potent T cell responses in vivo. Here, we analyzed the activation of speci®c T cells by MHC class II-bearing exosomes in vitro. The rat mast cell line, RBL-2H3, was engineered to express human class II molecules uniformly loaded with an antigenic peptide [HLA-DR1±hemagglutinin (HA)]. These cells secreted exosomes bearing DR1 class II molecules upon stimulation by a calcium ionophore or IgE receptor cross-linking. Exosomes bearing DR1±HA(306±318) complexes activated HA/DR1-speci®c T cells only weakly, whereas the cross-linking of such exosomes to latex beads increased stimulation of speci®c T cells. By contrast, the incubation of free exosomes with DC resulted in the highly ef®cient stimulation of speci®c T cells. Thus, exosomes bearing MHC class II complexes must be taken up by professional APC for ef®cient T cell activation.
Introduction
The endocytic pathway of antigen-presenting cells (APC) has several key characteristics accounting for their unique ability to elicit MHC class II-restricted T cell responses. Endosomes and lysosomes from these cells are compartments with an important role in antigen presentation, in which antigenic peptides associate with MHC class II molecules. Antigen-processing compartments were ®rst described in human B cell lines as multilaminar/multivesicular MHC class II compartments (MIIC) (1, 2) . Resident endosomal proteins, such as CD63, and MHC class II molecules accumulate in these compartments. In addition, the fusion of MIIC with the plasma membrane leads to the plasma membrane expression of peptide±MHC class II complexes and to the secretion of small vesicles, called exosomes, bearing MHC class II±peptide complexes. Although the secretion of exosomes has been reported in various hematopoietic cells including reticulocytes, platelets, B lymphocytes, mast cells and dendritic cells (DC) (3±8), the function of cell-derived exosomes remains unclear.
The accumulation of MHC class II±peptide complexes on the limiting membranes of exosomes derived from APC, such as B cells or DC, led to evaluation of the role of exosomes bearing MHC class II in the T cell response. High concentrations of B-Epstein±Barr virus (EBV)-derived exosomes have been shown to activate speci®c CD4 T cell clones directly (5) . Dendritic cell-derived exosomes have recently been reported to accumulate MHC class II and I molecules, along with costimulatory molecules (8, 9) . In addition, exosomes produced by DC exposed to tumor-derived antigenic peptides have been shown to induce a cytotoxic T lymphocyte-mediated response leading to the regression of established tumors in mice (8) . Thus, exosomes bearing MHC molecules and antigenic peptides induce potent T cell responses, although the stimulation of speci®c T cells with peptide-pulsed exosomes was consistently less ef®cient than the stimulation of intact cells by incubation with peptides (5, 8, 10) . This suggests that exosomes do not interact directly with effector cells. The precise mechanism of this phenomenon still remains to be understood.
Exosomes from platelets and mast cells are secreted upon cell activation, suggesting that exosomes may be involved in homeostasis or in¯ammatory reactions. Furthermore, bone marrow-derived mast cells (BMMC) and the mast cell line rat basophilic leukemia (RBL)-2H3 mostly accumulate MHC class II molecules in small vesicles contained in secretory granules. The exocytosis of mast cell secretory granules may be triggered by antigen-induced aggregation of the high-af®nity receptors (FceRI) for IgE (11) or exposure to a calcium ionophore. The activation of BMMC expressing MHC class II leads, as expected, to the release of exosomes bearing MHC class II.
Homogeneous and reliable preparations of exosomes, bearing a well-de®ned MHC class II±peptide complex, are a key tool for investigating exosome function. We explored the mechanisms of T cell activation by MHC class II + exosomes, by expressing HLA-DR1 a and b chains alone or in combination with an Ii chain mutant (IiHA), which carries a sequence encoding the antigenic hemagglutinin (HA) peptide (12) in place of the class II invariant chain peptide (CLIP) region (13) , in the RBL cell line RBL-2H3. Co-expression of the IiHA construct facilitated the endogenous loading of most of the MHC class II molecules present in RBL DR1IiHA cells with the HA peptide. The accumulation of MHC class II in secretory granules made it possible to induce the release of class II + exosomes by cross-linking IgE receptors or adding calcium ionophores. RBL DR1-derived exosomes loaded with HA peptide and RBL DR1IiHA-derived exosomes contain functional MHC class II complexes that stimulate speci®c CD4 + T cells weakly. Coupling exosomes to carrier beads increased the ef®ciency of T cell stimulation. In contrast, exosomes stimulated DR1±HA-speci®c CD4 + T cells very ef®ciently if they were ®rst incubated with murine DC. Thus, exosomes may need to be captured by DC to stimulate speci®c T cells ef®ciently.
Methods

Chemical reagents, antibodies and peptides
All chemicals used in this study were purchased from Sigma (St Louis, MO). RPMI 1640, FCS, PBS, penicillin, streptomycin, sodium pyruvate and L-glutamine were purchased from Gibco (Paisley, UK). We used the following mAb: L243 (22,23) which recognizes HLA-DR complexes devoid of the Ii chain, Tu È 36 (24) directed against HLA-DR alone or associated with the Ii chain, 1B5 (25) directed against HLA-DR a AD1 (26) an antirat CD63 mAb (a gift from Dr R. P. Siraganian, NIH, Bethesda, MA), LY1C6 an anti-rat lysosome-associated membrane protein (Lamp1) mAb (a gift from Dr W. Hunziker, Epalinges, Switzerland) and 1A12 an anti-rat CD81 mAb (27) (a gift from Dr J. P. Kinet, Harvard University, Boston, MA). Secondary antibodies included horseradish peroxidase-, FITC-, phycoerythrin (PE)-or Texas Red-coupled F(ab¢) 2 fragments and were obtained from Jackson ImmunoResearch (Jackson Laboratory, West Grove, PA). The HA306±318 peptide (PKYVKQNTLKLAT) (12) was synthesized by Synt:em (Nime, France). (28) and RBL-derived cell lines, HOM2, THA1.7, and Jurkat T cells were grown in RPMI 1640 supplemented with 10% FCS, 1% penicillin/streptomycin, 0.1% b-mercaptoethanol and 2% sodium pyruvate. The B-EBV cell line HOM2 is homozygous for HLA-DR1 (29) . THA1.7 are Jurkat T cells transfected with constructs encoding the a and b chains of a DR1±HA(306±318)-speci®c TCR (30) . Jurkat T cells were kindly provided by Dr O. Acuto (Institut Pasteur, Paris, France). RBL cells expressing I-A b Ii and TH30 T cell hybridoma were previously described (14) . The murine immature DC line D1 (H-2B) and BMD8 (H-2D) were kindly provided by Dr P. Ricciardi-Castagnoli (Centre of Cellular and Molecular Pharmacology, Milan, Italy), and cultured as previously described (15) .
Cells
RBL-2H3
DR expression in RBL cells
The cDNAs used for stable transfection in RBL-2H3 cells were inserted downstream from a Sra promoter (31) in expression vectors carrying resistance genes for hygromycin B (NTH2), neomycin (NTNeo) and zeocin (NTZeo). The HLA-DR1 a chain cDNA (32) was subcloned into the NTNeo vector, the HLA-DR1 b chain cDNA (33) into the NTHygro vector and the IiHA cDNA (13) into the NTZeo vector. The resulting a, b and IiHA constructs were then used to transfect the RBL-2H3 cell line as previously described (34) . Brie¯y, cells were electroporated at 260 V, 975 mF with 50 mg of linearized plasmid, using a BioRad (Marnes la Coquette, France) Gene Pulser II. Two days after transfection, the cells were transferred to selection medium. Surviving cells were cloned by limiting dilution. Clones were analyzed for surface MHC class II expression by cyto¯uoro-metry with a FACSCalibur¯ow cytometer (Becton Dickinson, Mountain View, CA).
Flow cytometry analysis
Cells were washed in 3% FCS/0.1% NaN 3 in PBS (FACS buffer) prior to staining as previously described (14) . Flow cytometry analysis was performed with a FACSCalibur machine using CellQuest software (Becton Dickinson). As exosomes are too small for FACScan analysis, we bound the exosomes to surfactant-free white aldehyde/sulfate latex beads (3.8 mm diameter) and concentrated at 1.5 Q 10 4 beads/ml (Interfacial; Dynamics, Portland, OR) (35) . We incubated 10 ml beads (corresponding to 1.5 Q 10 5 beads) with 30 mg exosomes for 10±15 min and then for 1 h at room temperature in a ®nal volume of 1 ml PBS. Glycine (100 mM) in PBS was added to the beads, which were then incubated for 30 min at room temperature to saturate the remaining binding sites. Beads were washed twice with FACS buffer, and analyzed with a FACSCalibur and CellQuest software.
Antigen-presentation assays APC (5 Q 10 4 ) were incubated with or without the HA peptide 5 mM in the presence of 5 Q 10 4 THA1.7 or Jurkat T cells/well for 24 h. Each experiment was performed in duplicate. We removed 50 ml of supernatant and froze it at ±80°C for 1 h. We measured IL-2 release from the T cell hybridoma by monitoring [ 3 H]thymidine incorporation in the IL-2-dependent CTL-L2 cell line. Cells were harvested after an additional 6 h incubation in the presence of 0.25 mCi [ 3 H]thymidine/well. Each point corresponds to the mean of duplicate samples, which differed by <5%.
For presentation assays with exosomes and exosomes cross-linked to beads, 5 Q 10 4 THA1.7 or Jurkat T cells/well were incubated with the corresponding exosome preparation and incubated with or without the HA peptide (0±10 or 50 mM). For exosome antigen-presentation assays in the presence of D1 DC, exosomes derived from RBL DR1 or RBL DR1IiHA were incubated with 5 Q 10 4 THA1.7 cells in the presence or absence of the HA peptide, with or without 5 Q 10 4 D1 cells. For exosome antigen-presentation assays in the presence of BMD8 DC, exosomes derived from RBL I-A b Ii were incubated with 5 Q 10 4 TH30 cells in the presence of the I-E a 52±68 peptide (10 mM) with 5 Q 10 4 BMD8 cells. After 24 h, IL-2 release was assayed as described above (36) .
Exosome puri®cation
Exosomes were prepared from supernatants of RBL-2H3 cells and derived cell lines, generally degranulated by incubation with a calcium ionophore (1 mM ionomycin or A23187) for 30 min at 37°C (37) or by cross-linking of FceRI as previously described (38) . Brie¯y, cells were incubated with anti-DNP IgE for 20 h at 37°C and degranulation was then triggered by adding 10 mg/ml DNP-BSA and incubating for various periods of time. Exosomes were isolated as previously described (5). Brie¯y, cell supernatants were successively centrifuged at 300 g for 10 min, 1200 g for 20 min, 3000 g for 30 min and ®nally 70,000 g for 1 h. The exosome pellet was washed in PBS, centrifuged at 70,000 g for 1 h and resuspended in PBS and protein concentration determined by Bradford assay (BioRad).
For the immunoisolation of exosomes, 5 ml latex beads (corresponding to 0.75 Q 10 5 beads) were incubated overnight with 15 mg of puri®ed anti-CD63 mAb at 4°C. Binding sites were saturated by incubation in 100 mM glycine in PBS for 30 min at room temperature and in the beads were then washed in FACS buffer. We incubated 10 ml beads with 30 mg puri®ed exosomes (or FCS as negative control) and carried out labeling for FACS analysis as described above for exosomes directly coupled to beads.
Sucrose gradient
RBL DR1 exosomes (100 mg) were resuspended in 2 ml 2.5 M sucrose, 20 mM HEPES/NaOH, pH 7.2. A linear sucrose gradient (2.0±2.5 M sucrose, 20 mM HEPES/NaOH, pH 7.2) was layered on top of the exosome suspension in a SW41 tube (Beckman Instruments, Gagny, France). Gradients were centrifuged for 15 h at 100,000 g and a 1-ml fraction was collected from the top of the tube. Densities were evaluated using a refractometer. Membranes were collected from the collected fractions after centrifugation at 70,000 g for 1 h at 4°C in TLA 100.4 tubes (Beckman Instruments). Exosome pellets were solubilized in reducing Laemmli buffer and heated at 95°C for 5 min before analysis by SDS±PAGE and Western blotting.
Western blotting
Cells were lysed in 0.5% Triton, 300 mM NaCl, 50 mM Tris, pH 7.4 in PBS supplemented with 10 mg/ml each of leupeptin, chemostatin, aprotinin, pepstatin, N-ethyl maleinide and 1 mM PMSF. Cell or exosome lysates were diluted in reducing Laemmli buffer and heated at 95°C for 5 min before analysis on SDS±12% polyacrylamide gels. Proteins were transferred to a PVDF membranes (Millipore, Bedford, MA). The membranes were incubated in blocking solution, then with IB5 [an anti-DR mAb (25) ] and ®nally with horseradish peroxidaselabeled donkey anti-mouse IgG secondary antibody (Jackson Laboratory). Antibody binding was detected by chemiluminescence, using an ECL kit (Boehringer Mannheim, Mannheim, Germany).
Immunoelectron microscopy RBL DR1 cells (degranulated or not) were ®xed by incubation in a mixture of 2% paraformaldehyde in phosphate buffer 0.2 M, pH 7.4 and 0.125% glutaraldehyde for 2 h at room temperature. Fixed cells were processed for ultrathin sectioning and immunolabeling as previously described (6) . Cells were washed with phosphate buffer 0.2 M, pH 7.4 and phosphate buffer 0.2 M, pH 7.4/50 mM glycine, and were then embedded in 7.5 % gelatin. Small blocks were in®ltrated with 2.3 M sucrose at 4°C for 2 h and then frozen in liquid nitrogen. Ultrathin cryosections prepared with a Leica ultracut FCS (Wien, Austria) were retrieved in a mixture of 2% methylcellulose and 2.3 M sucrose (v/v), and indirectly immunogold labeled by incubation with the rat monoclonal anti-HLA-DR1 antibody L243 followed by a rabbit anti-mouse antibody (Dako, Copenhagen, Denmark). Antibodies were detected with Protein A coupled to 10-nm gold particles (purchased from Dr J. W. Slot, Department of Cell Biology, Utrecht University, The Netherlands). The sections were contrast stained, embedded in a mixture of methylcellulose and uranyl acetate, and viewed under a CM120 Twin Phillips electron microscope (Eindhoven, The Netherlands). For electron microscopy of the isolated exosomes, the pellets from the 70,000 g centrifugation were placed on Formvar carboncoated electron microscopy grids, ®xed as above, immunolabeled and stained using the method described for ultrathin cryosections. Exosomes from RBL I-A b Ii cells were labeled in similar conditions using M5/114 mAb (14) Results RBL cells expressing HLA-DR1 chains together with the IiHA construct are ef®cient APC To generate mast cell lines expressing MHC class II±peptide complexes, we transfected the RBL cell line RBL-2H3 with cDNAs encoding HLA-DR1 a and b chains with or without a previously described IiHA construct (Fig. 1A) . We failed to detect any endogenous MHC class II in our RBL-2H3 clone using the anti-rat MHC class II, OX6 (data not shown). The core CLIP sequence of this human Ii-derived construct has been replaced by the sequence encoding the antigenic HA306±318 peptide of in¯uenza virus HA (13) . After selection and cloning, one clone for each combination was selected on levels of surface MHC class II expression. RBL DR1 cells, RBL DR1IiHA cells and HOM2 B-EBV cells displayed similar levels of surface expression of MHC class II molecules, as determined by cyto¯uorimetry (Fig. 1B) .
We then tested the ability of these cells to stimulate Jurkat T cells expressing or not a speci®c TCR recognizing HLA-DR1± HA306±318, known as THA1.7. The cells were incubated with various concentrations of HA peptide and IL-2 secretion by T cells was measured in the supernatants. Both B-EBV Hom2 and RBL DR1 cells ef®ciently stimulated the THA1.7 cell line on addition of HA peptide, whereas no stimulation of non-speci®c Jurkat T cells was observed in the same conditions (Fig. 1C) . Parental RBL cells were not able to stimulate THA1.7 cells upon addition of HA peptide (Fig.1C) . Interestingly, the concentration of HA peptide required to generate halfmaximal stimulation was similar for HOM2 and RBL DR1 cells (~0.1 mM). As expected, RBL DR1IiHA cells stimulated THA1.7-speci®c T cells in the absence of HA peptide, whereas non-speci®c Jurkat cells were not stimulated. Furthermore, the addition of HA peptide to RBL DR1IiHA cells did not increase THA1.7 stimulation (Fig. 1C) . We further investigated HA loading of RBL DR1IiHA cells by determining the number of presenting cells required to stimulate THA1.7 cells in the presence or absence of a saturating concentration of HA peptide (5 mM). Upon addition of HA peptide, RBL DR1 cells gave half-maximal stimulation with as little as 50 cells/well, whereas HOM2 cells required~20 times more cells to induce a similar level of THA1.7 stimulation. The ability of RBL DR1IiHA cells to stimulate THA1.7 cells was independent of the presence of peptide and half-maximal stimulation was achieved with~30 cells/well. Therefore, RBL DR1IiHA cells were ef®ciently loaded with the endogenous HA peptide from the IiHA construct and these cells were competent for antigen presentation.
RBL cells secrete vesicles bearing HLA-DR1 molecules
As MHC class II molecules accumulated in the secretory granules of mast cells, we analyzed the distribution of HLA-DR molecules on ultrathin cryosections of RBL DR1 cells by immunogold labeling with the anti-DR antibody, L243. MHC class II molecules were mostly detected in intracellular compartments similar to multivesicular bodies (MVB) containing large numbers of vesicles, but faint labeling was also observed at the plasma membrane ( Fig. 2A) . The segregation of CD63, Lamp1 and serotonin, together with HLA-DR1, in these MVB (data not shown) suggests that human MHC class II molecules accumulated in the secretory granules of RBL2H3 cells, as previously reported by our group (14) . We therefore determined whether mast cell degranulation induced the release of small vesicles bearing MHC class II.
RBL cell degranulation was induced by cross-linking IgE receptors with IgE anti-DNP/DNP-BSA immune complexes or by adding a calcium ionophore (A23187 or ionomycin). Supernatants were collected after stimulation for various periods of time, ultracentrifuged and the pellets analyzed by Western blotting with an anti-HLA-DR a mAb. All cell lysates were loaded on the same gel and subjected to electrophoresis to estimate the number of DR molecules associated with these vesicles. The amount of DR1 a chain present in the supernatant gradually increased over time, reaching a maximum at 30 min (Fig. 2B) . The addition of either of the calcium ionophores induced levels of DR1 secretion twice as high as those induced by IgE receptor cross-linking. Comparison of the DR1 a chain signals observed for vesicle preparations (obtained from 10 7 cells) with those obtained from cells lysates (1±2 Q 10 5 cells) indicated that almost 2% of total MHC class II molecules were secreted upon mast cell degranulation (Fig. 2B) .
To con®rm that MHC class II-containing vesicles were secreted, we prepared ultrathin cryosections of RBL DR1 cells following IgE receptor cross-linking and analyzed them by immunogold labeling with the anti-DR antibody, L243. Exocytosis pro®les with DR1-labeled vesicles were detected (Fig. 2C) . We puri®ed vesicles from the supernatant of stimulated RBL DR1 cells by ultracentrifugation and analyzed them directly by whole-mount electron microscopy. Heterogeneous populations of vesicles 60±80 nm in diameter were detected (Fig. 2D) . Most had single membranes, but those with double membranes had denser lumina and frequently displayed positive HLA-DR labeling (Fig. 2D) . Contaminations of vesicles preparations by endoplasmic reticulum membranes were excluded by the lack of any endoplasmic reticulum protein (calnexin) in exosomes pellets (data not shown).
Thus, RBL DR1 cells can secrete large numbers of small vesicles carrying HLA-DR1 molecules, which have morphological features in common with previously described exosomes.
Characterization of the secreted vesicles
To determine whether the vesicles secreted by RBL DR1 cells were indeed exosomes, vesicles obtained by ultracentrifugation were subjected to sucrose gradient sedimentation and the MHC class II content of each fraction was analyzed by western blotting. Most of the MHC class II molecules were found in fractions with a sucrose density of 1.16±1.21 g/ml (Fig. 3A) . Thus, the vesicles bearing MHC class II sedimented at a slightly higher density than that previously reported for exosomes (1.135 g/ml). As these vesicles originated from MVB, as described for exosomes, we analyzed their endocytic/lysosomal pathway protein content. The vesicles were too small for direct analysis by cyto¯uorimetry and most of the antibodies against rat lysosomal proteins do not work in Western blotting experiments. We therefore analyzed the protein composition of the vesicles by coupling the vesicles to 3.8-mm latex beads and immunolabeling with FITC-conjugated speci®c antibodies. FACScan analysis of the vesicles attached to the beads revealed that they contained large amounts of CD63, CD81 and MHC class II, but almost no Lamp1 (Fig. 3B) . A key feature of exosomes is the association of MHC class II molecules with tetraspanin on the same vesicle. We investigated whether the vesicles secreted by RBL cells contained CD63 and DR1, by coating beads with the anti-CD63 mAb AD1 and incubating them with vesicles prepared from RBL DR1 cells. We then washed the beads and assessed the amount of DR1 associated with the beads using a PEconjugated anti-DR mAb. Signi®cant speci®c labeling was observed, suggesting that a population of vesicles carried both DR and CD63 (Fig. 3C) .
Upon stimulation, RBL cells secrete vesicles of 60±80 nm in diameter, which¯oat on sucrose gradients, and bear CD63, HLA-DR and CD81 molecules. We therefore concluded that these vesicles had features similar to those previously described for exosomes in B cells, DC and mast cells. We coupled 30 mg of microvesicles or of BSA to 10 ml latex beads and tested for surface expression of CD63 (AD1 mAb), Lamp1 (LY1C6 mAb), CD81 (1A12 mAb), and mature HLA-DR1 (L243 mAb) and total HLA-DR1 (Tu È 36 mAb). (C) Latex beads pre-incubated with the anti-CD63 mAb AD1 were used to immunoisolate microvesicles secreted from RBL DR1 cells. Beads were further analyzed by¯ow cytometry for HLA-DR surface expression using PE-coupled L243 and Tu È 36 mAb. In (B) and (C), gray histograms correspond to the same beads incubated with PEcoupled isotypes controls.
RBL exosomes carry functionally competent DR molecules
As we were able to produce homogeneous and reliable preparations of exosomes bearing MHC class II molecules from RBL DR1 and RBL DR1IiHA cells, we used these exosomes to investigate the activation of speci®c T cells in vitro. We investigated whether DR1 + exosomes directly activated T cell by adding various amounts of exosomes to THA1.7 cells or Jurkat T cells and measuring IL-2 secretion into the cell supernatant. Both exosomes from RBL DR1 cells in the presence of saturating amounts of the HA peptide and exosomes from RBL DR1IiHA cells without peptide stimulated THA1.7 cells. No THA1.7 cell stimulation was observed with empty DR1 exosomes and DR1±HA exosomes did not stimulate irrelevant Jurkat T cells (Fig. 4A) . However, the stimulation of speci®c T cells with HA-loaded DR1 exosomes was not ef®cient because THA1.7 cell stimulation was detectable only upon the addition of a large quantity of exosomes (50 mg/well).
Soluble MHC class II molecules are known to stimulate speci®c T cells inef®ciently. There might therefore be too few MHC class II molecules on the surface of exosomes to stimulate T cells. DR1 or DR1IiHA exosomes were therefore cross-linked to latex beads (3.8 mm diameter) and used in a similar antigen-presentation assay. After cross-linking to beads, exosomes from RBL DR1 cells ef®ciently stimulated the THA1.7 cell line only in the presence of saturating amounts of peptide, whereas no stimulation of Jurkat T cells was observed in the same conditions (Fig. 4B, left panel) . Similar results were obtained with exosomes from RBL DR1IiHA cells in the absence of peptide (Fig. 4B, right panel) , con®rming that the HLA-DR molecules carried by these exosomes are effectively loaded with HA peptide. In both cases, 0.3 mg of exosomes was enough to induce the half-maximal stimulation of THA1.7 cells. Finally, we carried out a peptide titration of RBL DR1 exosomes cross-linked to beads. Half-maximal stimulation of the THA1.7 cell line was obtained at a concentration of 1 mM HA peptide (Fig. 4C) , which is only 10 times higher than that with RBL DR1 cells (Fig. 1C) . These data indicate that exosomes bearing HA/DR1 complexes speci®c-ally stimulate T cells. However, the density of MHC class II molecules at the surface of exosomes, the size or composition of exosomes may be limiting for the ef®cient induction of T cell stimulation in vitro.
Exosomes ef®ciently stimulate speci®c T cells after transfer to DC DC are classical antigen-presenting cells involved in T cell priming. As exosomes bearing MHC class II±peptide complexes did not ef®ciently stimulate speci®c T cells, we investigated the role of DC in exosome-dependent T cell stimulation. The murine immature DC line D1 (15) was used in an antigen-presentation assay in which various amounts of DR1 exosomes were added to D1 cells in the presence or absence of the HA peptide. DR1 exosomes ef®ciently stimulated THA1.7 cells if 10 mM HA peptide was added (Fig. 5, left  panel) . Similarly, exosomes from RBL DR1IiHA cells ef®ciently stimulated the THA1.7 cell line independently of the presence of HA peptide (Fig. 5, right panel) . Both types of exosomes stimulated T cells if 0.3±0.6 mg of exosome preparation was added to each well, whereas in the absence of DC, 100 times more exosomes were required to achieve similar levels of T cell stimulation (Fig. 4A ) and no T cell stimulation was achieve when similar exosomes were incubated in the same conditions with B cells (data not shown). Thus, DC facilitate the induction of ef®cient exosome-dependent T cell stimulation.
Similar results were obtained with murine MHC class II + exosomes upon incubation with murine DC. Exosomes were prepared from RBL cells expressing I-Ab Ii complexes and were then characterized for MHC class II expression. By electron microscopy, whole-mount I-A b Ii exosomes preparation displayed heterogeneous populations of vesicles similar in size and morphology to those isolated from RBL DR1 cells (Fig. 5B, left panel) . Immunolabeling with M5/114 mAb (Fig. 5B, right panel) , whereas no TH 30 stimulation was observed in the absence of I-E d a 52±68 peptide or BMD8 DC (Fig. 5B, right panel) . T cells stimulation by class II + exosomes required therefore incubation of exosomes with DC.
These results suggested that exosomes were transferred to DC. We investigated this possibility by incubating D1 cells for various periods of time with 50 mg of DR1 exosomes at 37°C. We then detected DR1 molecules by FACScan analysis with L243 mAb. DR1 molecules were ®rst detected at the surface of DC after 1 h (data not shown) and they increased in number thereafter, reaching a maximum at 18 h (Fig. 5C ). If THA1.7 cells (Fig. 5C ) or mouse B lymphocytes (not shown) were incubated in the same conditions with similar concentrations of DR1 exosomes in the presence of HA peptide, no L243 + MHC class II molecules were detected at the surface of the cells. Thus, the stimulation of T cells by MHC class II + exosomes requires the incubation of these exosomes with DC.
Discussion
We show here that RBL cells expressing HLA-DR1 molecules secrete vesicles able to stimulate MHC class II-restricted T cells. These vesicles were probably produced by MVB, as suggested by immunoelectron microscopy pro®les, and were 60±80 nm in diameter. They had a density of 1.2 g/ml on a sucrose gradient, and expressed CD63, HLA-DR and CD81 molecules. On the basis of all these criteria, these microvesicles resembled the exosomes produced by human B cells originally described by Raposo et al. (5) . One important advantage of our cellular model is that exosome secretion can be induced very ef®ciently, resulting in reliable exosome production.
To produce exosomes carrying a single type of MHC class II±peptide complex, we made use of our previously characterized construct derived from the Ii chain (13) . The core CLIP sequence of this construct has been replaced by a sequence encoding the HA306±318 antigenic peptide. We found that RBL cells transfected with this construct together with constructs encoding the DR a and b chains expressed mainly DR1±HA complexes at the cell surface. The addition of exogenous HA peptide did not increase the capacity of RBL DR1IiHA to stimulate speci®c T cells. A very similar construct has been characterized and used in HLA-DR1-transfected human embryonic kidney cell line 293, generating similar results. Van Bergen et al. also eluted peptides from the DR1 molecules and showed that most contained the HA peptide, with ragged ends corresponding to the¯anking sequences of the Ii construct (16) .
Both RBL DR1 and RBL DR1IiHA cells were remarkably ef®cient at stimulating speci®c T cells. RBL DR1 cells achieved half-maximal stimulation of THA1.7 cells with 1/10 the amount of HA peptide required to achieve the same level of stimulation by HOM2, a B-EBV cell line homozygous for DR1. This suggests that the DR1 molecules in RBL cells were more easily loaded with peptide than those in HOM2 cells, as MHC class II levels at the surface were similar for the two cell types. The loading of MHC class II with exogenous peptide was recently shown to require active recycling of MHC class II. Differences in recycling capacity may account for the observed discrepancy. It is also possible that the expression of human DR molecules in a rat cell line (RBL DR1) may have resulted in a lower level of peptide occupancy or the binding of peptides with lower af®nity. Titration of the number of RBL DR1IiHA or RBL DR1 cells in the presence of saturating amounts of HA peptide revealed that as few as 100 cells were able to generate half-maximal stimulation of 5 Q 10 4 T cells, whereas T cell hybridoma and 10 mM I-E d a52±68 peptide. T cell stimulation was evaluated as described in Fig. 1(C) . Similar experiments were performed in the absence of BMD8 murine DC (black squares). (C) D1 cells or THA1.7 cells were incubated overnight with 30 mg/ml DR1 exosomes and MHC class II molecules were detected by¯ow cytometry using L243 mAb. 1000 HOM2 cells were required to generate a similar response. This provides support for the idea that RBL DR1 cells are easily loaded with exogenous peptide. RBL DR1IiHA and RBL DR1 generated similar maximal responses in the presence of HA peptide, supporting the notion that, in both situations, the majority of the DR1 molecules were loaded with HA peptide. We previously showed that murine MHC class II molecules (I-A b ) may be expressed as functional molecules in RBL cells (14) . Therefore, RBL cells are a useful model for expressing MHC class II complexes loaded with a given peptide, supplied exogenously or introduced via an Ii chainderived construct.
We found that MHC class II molecules were present on exosomes secreted by RBL DR1 cells exposed to appropriate stimuli. We studied their capacity to stimulate T cells and observed that the threshold at which T cells responded increased by a factor of 2 log, for a given quantity of exosomes, if the exosomes were chemically cross-linked to beads. This suggests that there are too few MHC class II molecules per exosome to create an immunological synapse on the target T cell. Indeed, it has been established that a minimum of~10 MHC class II molecules are needed for ef®cient reorganization of the TCR at the T cell surface, which in turn leads to a signal transduction cascade activating the T cell (17, 18) .
Interestingly, immature mouse DC, like beads, increased the capacity of exosomes to stimulate T cells by a factor of 2 log. Other cell types, such as B cells and mast cells, had no such effect (not shown). The transfer of vesicles from APC to T cells following speci®c interaction has been reported before (19) . It is unclear whether exosomes play a physiological role in vivo. However, immunization with exosomes proved to be very ef®cient in a mouse in vivo tumor model (8) . The signi®cant enhancement by DC of the stimulatory capacity of MHC class II molecules carried by exosomes in vitro suggests that DC may have a similar function in vivo. They may capture circulating exosomes and present them to T cells. Indeed, follicular DC (FDC) have been demonstrated to bind MHC class II + microvesicles, which closely resemble exosomes in protein content and morphology, speci®cally to their surface (20) . Such a role would also be compatible with the reported ability of FDC to trap circulating viral particles, similar in size to exosomes, at their surface (21) . It is unclear whether DC fuse with exosomes and process them, and the possibility of such presentation in vivo for the maintenance of peripheral tolerance and induction of speci®c immune responses is also unknown. However, our model should provide a useful tool for addressing these important issues in future research.
